Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 20, 2017
Pharmacy Choice - Pharmaceutical News - Actelion receives FDA approval for 32mg Tracleer to treat paediatric PAH patients [Arab Finance (Egypt)] - November 20, 2017

Pharmacy News Article

 9/8/17 - Actelion receives FDA approval for 32mg Tracleer to treat paediatric PAH patients [Arab Finance (Egypt)]

Actelion Pharmaceuticals US, a Janssen Pharmaceutical Company of Johnson & Johnson, has received US Food and Drug Administration (FDA) approval for Tracleer (bosentan) to be used in paediatric patients with idiopathic or congenital pulmonary arterial hypertension (PAH).

The FDA has granted approval for a new 32mg tablet for oral suspension for Tracleer to treat PAH patients aged three and older.

PAH is a chronic and progressive disease that results in abnormally high blood pressure in the arteries between the heart and lungs of an affected person.

The life-threatening disorder does not allow the blood to flow normally through the lungs and forces the patients heart to work harder.

Tracleer is an orally active endothelin receptor antagonist (ERA) that can be used to treat PAH patients by blocking the effects of the extra endothelin produced by their bodies.

The therapy has the potential to improve pulmonary vascular resistance (PVR), which is expected to improve the patients exercising ability.

"Actelion has focused on the needs of the PAH community since Tracleer, our first treatment for PAH, was approved in 2001."

Actelion Pharmaceuticals US Medical senior vice-president Dr Gary Palmer said: Actelion has focused on the needs of the PAH community since Tracleer, our first treatment for PAH, was approved in 2001.

Were pleased our portfolio of treatments continues to grow and paediatric PAH patients will now have an FDA-approved treatment option available.

The Actelion medicine is currently the first treatment approved by the FDA for paediatric PAH patients in the US.

The company expects to make the 32mg oral treatment available by the fourth quarter of this year.



(c) 2017 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 20: Obesity Management: Overview of Pharmacotherapy
Last Chance
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415